Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis

(1) Background: With new potential drug targets emerging, combination therapies appear attractive to treat non-alcoholic steatohepatitis (NASH) and fibrosis. Chemokine receptor CCR2/5 antagonists can improve fibrosis by reducing monocyte infiltration and altering hepatic macrophage subsets. Fibrobla...

Descripción completa

Detalles Bibliográficos
Autores principales: Puengel, Tobias, Lefere, Sander, Hundertmark, Jana, Kohlhepp, Marlene, Penners, Christian, Van de Velde, Frederique, Lapauw, Bruno, Hoorens, Anne, Devisscher, Lindsey, Geerts, Anja, Boehm, Stephanie, Zhao, Qihong, Krupinski, John, Charles, Edgar D., Zinker, Bradley, Tacke, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224277/
https://www.ncbi.nlm.nih.gov/pubmed/35743140
http://dx.doi.org/10.3390/ijms23126696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224277/
https://www.ncbi.nlm.nih.gov/pubmed/35743140
http://dx.doi.org/10.3390/ijms23126696

Ejemplares similares